Research Article

Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer

Table 1

Baseline characteristics of patient population according to diagnostic period.

Baseline characteristicsNumber of patients (%)-value
Diagnostic periodTotal
2005–20072008–2010

Total number of patients499478977

Gender0.094
 M301 (60.3%)263 (55.0%)564 (57.7%)
 F198 (39.7%)215 (45.0%)413 (42.3%)
Mean age at diagnosis (years)68.6 68.8 68.40.619

ECOG<0.001
 023 (5.5%)40 (8.6%)63 (7.2%)
 1202 (48.6%)233 (50.3%)435 (49.5%)
 2103 (24.8%)124 (26.8%)227 (25.8%)
 361 (14.7%)59 (12.7%)120 (13.7%)
 427 (6.5%)7 (1.5%)34 (3.9%)

T stage0.567
T195 (21.7%)87 (19.0%)182 (20.3%)
T269 (15.8%)82 (17.9%)151 (16.9%)
T3191 (43.6%)210 (45.9%)401 (44.8%)
T483 (18.9%)79 (17.2%)162 (18.1%)

N stage0.507
N0305 (61.1%)302 (63.2%)607 (62.1%)
N1194 (38.9%)176 (36.8%)370 (37.9%)

Number of metastatic sites0.823
 1150 (30.1%)135 (28.2%)285 (29.2%)
 2159 (31.9%)156 (32.6%)315 (32.2%)
 ≥3190 (38.1%)187 (39.1%)377 (38.6%)

Metastatic sites
 Distant lymph nodes112 (22.4%)133 (27.8%)245 (25.1%)0.052
 Lungs297 (59.5%)302 (63.2%)599 (61.3%)0.240
 Bone154 (30.9%)159 (33.3%)313 (32.0%)0.421
 Adrenal gland101 (20.2%)87 (18.2%)188 (19.2%)0.419
 Liver102 (20.4%)96 (20.1%)198 (20.3%)0.890
 Cerebral30 (21.0%)25 (24.0)55 (22.3%)0.568

Histology tumor type0.800
 Clear cell carcinoma285 (89.3%)299 (88.7%)584 (89.0%)
 Other34 (10.7%)38 (11.3%)72 (11.0%)

Nephrectomy246 (49.3%)272 (56.9%)518 (53.0%)0.017
Hemoglobin < LLN193 (60.5%)207 (60.5%)400 (60.5%)0.995
CRP > ULN211 (82.1%)216 (74.7%)427 (78.2%)0.038

Histological diagnosis was missing for 318 patients: T stage for 78, hemoglobin for 313, CRP for 428, and ECOG status for 95 patients. The percentages in the second column were calculated only for the group of patients for whom data on these variables were available. Abbreviations: IQR = interquartile range; LLN = lower limit of normal; ULN = upper limit of normal.